Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridoxamine for Autism Spectrum Disorder (Phase 2, Japan)
jRCT2091220438Phase 2Completed
- Sponsor
- Tohoku University Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pyridorin in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Tohoku University Hospital. Primary endpoint: Change in excitatory subscale score of ABC-J from baseline. Started Mar 2020; status: completed.
02
Drugs
pyridorin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on jRCT2091220438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220438.